Mechanism of PARP inhibitor resistance and potential overcoming strategies

Lindahl, 1995, Post-translational modification of poly(ADP-ribose) polymerase induced by DNA strand breaks, Trends Biochem Sci, 20, 405, 10.1016/S0968-0004(00)89089-1 Gibson, 2012, New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs, Nat Rev Mol Cell Biol, 13, 411, 10.1038/nrm3376 Amé, 2004, The PARP superfamily, Bioessays, 26, 882, 10.1002/bies.20085 Hassa, 2008, The diverse biological roles of mammalian PARPS, a small but powerful family of poly-ADP-ribose polymerases, Front Biosci, 13, 3046, 10.2741/2909 Langelier, 2012, Structural basis for DNA damage-dependent poly(ADP-ribosyl)ation by human PARP-1, Science, 336, 728, 10.1126/science.1216338 Langelier, 2013, PARP-1 mechanism for coupling DNA damage detection to poly(ADP-ribose) synthesis, Curr Opin Struct Biol, 23, 134, 10.1016/j.sbi.2013.01.003 Caldecott, 2020, Mammalian DNA base excision repair: dancing in the moonlight, DNA Repair, 93, 10.1016/j.dnarep.2020.102921 Beard, 2019, Eukaryotic base excision repair: new approaches shine light on mechanism, Annu Rev Biochem, 88, 137, 10.1146/annurev-biochem-013118-111315 Demin, 2021, XRCC1 prevents toxic PARP1 trapping during DNA base excision repair, Mol Cell, 81, 3018, 10.1016/j.molcel.2021.05.009 Gao, 2017, SSRP1 cooperates with PARP and XRCC1 to facilitate single-strand DNA break repair by chromatin priming, Cancer Res, 77, 2674, 10.1158/0008-5472.CAN-16-3128 Chen, 2022, Truncated PARP1 mediates ADP-ribosylation of RNA polymerase III for apoptosis, Cell Discov, 8, 3, 10.1038/s41421-021-00355-1 Gibson, 2016, Chemical genetic discovery of PARP targets reveals a role for PARP-1 in transcription elongation, Science, 353, 45, 10.1126/science.aaf7865 Sung, 2006, Mechanism of homologous recombination: mediators and helicases take on regulatory functions, Nat Rev Mol Cell Biol, 7, 739, 10.1038/nrm2008 Yap, 2011, Poly(ADP-ribose) polymerase (PARP) inhibitors: exploiting a synthetic lethal strategy in the clinic, CA Cancer J Clin, 61, 31, 10.3322/caac.20095 Ang, 2010, Transcription inhibition by platinum-DNA cross-links in live mammalian cells, J Am Chem Soc, 132, 7429, 10.1021/ja101495v Fong, 2010, Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval, J Clin Oncol, 28, 2512, 10.1200/JCO.2009.26.9589 Ledermann, 2014, Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial, Lancet Oncol, 15, 852, 10.1016/S1470-2045(14)70228-1 Pujade-Lauraine, 2017, Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21):a double-blind, randomised, placebo-controlled, phase 3 trial, Lancet Oncol, 18, 1274, 10.1016/S1470-2045(17)30469-2 Citarelli, 2010, Evolutionary history of the poly(ADP-ribose) polymerase gene family in eukaryotes, BMC Evol Biol, 10, 308, 10.1186/1471-2148-10-308 Gagné, 2008, Proteome-wide identification of poly(ADP-ribose) binding proteins and poly(ADP-ribose)-associated protein complexes, Nucleic Acids Res, 36, 6959, 10.1093/nar/gkn771 El-Khamisy, 2003, A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage, Nucleic Acids Res, 31, 5526, 10.1093/nar/gkg761 Lord, 2017, PARP inhibitors: synthetic lethality in the clinic, Science, 355, 1152, 10.1126/science.aam7344 Bell, 2021, Single-molecule measurements reveal that PARP1 condenses DNA by loop stabilization, Sci Adv, 7, 10.1126/sciadv.abf3641 Langelier, 2018, PARP family enzymes: regulation and catalysis of the poly(ADP-ribose) posttranslational modification, Curr Opin Struct Biol, 53, 187, 10.1016/j.sbi.2018.11.002 Zandarashvili, 2020, Structural basis for allosteric PARP-1 retention on DNA breaks, Science, 368, 10.1126/science.aax6367 Helleday, 2011, The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings, Mol Oncol, 5, 387, 10.1016/j.molonc.2011.07.001 Saleh-Gohari, 2005, Spontaneous homologous recombination is induced by collapsed replication forks that are caused by endogenous DNA single-strand breaks, Mol Cell Biol, 25, 7158, 10.1128/MCB.25.16.7158-7169.2005 Krastev, 2022, The ubiquitin-dependent ATPase p97 removes cytotoxic trapped PARP1 from chromatin, Nat Cell Biol, 24, 62, 10.1038/s41556-021-00807-6 Cong, 2021, Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency, Mol Cell, 81, 3128, 10.1016/j.molcel.2021.06.011 Saha, 2021, Replication-dependent cytotoxicity and Spartan-mediated repair of trapped PARP1-DNA complexes, Nucleic Acids Res, 49, 10493, 10.1093/nar/gkab777 Mateo, 2019, A decade of clinical development of PARP inhibitors in perspective, Ann Oncol, 30, 1437, 10.1093/annonc/mdz192 Dias, 2021, Understanding and overcoming resistance to PARP inhibitors in cancer therapy, Nat Rev Clin Oncol, 18, 773, 10.1038/s41571-021-00532-x Fong, 2009, Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers, N Engl J Med, 361, 123, 10.1056/NEJMoa0900212 Banerjee, 2021, Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004):5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet Oncol, 22, 1721, 10.1016/S1470-2045(21)00531-3 Frenel, 2022, Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial, Ann Oncol, 33, 1021, 10.1016/j.annonc.2022.06.011 Robinson, 2021, Treatment and patient selection for patients with metastatic castration-resistant prostate after progression on docetaxel and abiraterone/enzalutamide: when to play your CARD and when to do your PARP, Eur Urol, 80, 123, 10.1016/j.eururo.2021.03.001 Mateo, 2020, Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial, Lancet Oncol, 21, 162, 10.1016/S1470-2045(19)30684-9 Carreira, 2021, Biomarkers associating with PARP inhibitor benefit in prostate cancer in the TOPARP-B trial, Cancer Discov, 11, 2812, 10.1158/2159-8290.CD-21-0007 de Bono, 2020, Olaparib for metastatic castration-resistant prostate cancer, N Engl J Med, 382, 2091, 10.1056/NEJMoa1911440 Mateo, 2015, DNA-repair defects and olaparib in metastatic prostate cancer, N Engl J Med, 373, 1697, 10.1056/NEJMoa1506859 Golan, 2019, Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer, N Engl J Med, 381, 317, 10.1056/NEJMoa1903387 Reiss, 2021, Phase II study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic variant in BRCA1, BRCA2, or PALB2, J Clin Oncol, 39, 2497, 10.1200/JCO.21.00003 Swisher, 2021, Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2), Nat Commun, 12, 2487, 10.1038/s41467-021-22582-6 González-Martín, 2019, Niraparib in patients with newly diagnosed advanced ovarian cancer, N Engl J Med, 381, 2391, 10.1056/NEJMoa1910962 Mirza, 2016, Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer, N Engl J Med, 375, 2154, 10.1056/NEJMoa1611310 Ai, 2021, Efficacy and safety of niraparib as maintenance treatment in patients with extensive-stage SCLC after first-line chemotherapy: a randomized, double-blind, phase 3 study, J Thorac Oncol, 16, 1403, 10.1016/j.jtho.2021.04.001 Litton, 2018, Talazoparib in patients with advanced breast cancer and a germline BRCA mutation, N Engl J Med, 379, 753, 10.1056/NEJMoa1802905 de Bono, 2021, Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial, Lancet Oncol, 22, 1250, 10.1016/S1470-2045(21)00376-4 Li, 2021, An open-label, multicenter, single-arm, phase II study of fluzoparib in patients with germline BRCA1/2 mutation and platinum-sensitive recurrent ovarian cancer, Clin Cancer Res, 27, 2452, 10.1158/1078-0432.CCR-20-3546 Li, 2022, Fuzuloparib maintenance therapy in patients with platinum-sensitive, recurrent ovarian carcinoma (FZOCUS-2): a multicenter, randomized, double-blind, placebo-controlled, phase III trial, J Clin Oncol, 40, 2436, 10.1200/JCO.21.01511 Murai, 2012, Trapping of PARP1 and PARP2 by clinical PARP inhibitors, Cancer Res, 72, 5588, 10.1158/0008-5472.CAN-12-2753 Ronson, 2018, PARP1 and PARP2 stabilise replication forks at base excision repair intermediates through Fbh1-dependent Rad51 regulation, Nat Commun, 9, 746, 10.1038/s41467-018-03159-2 Papeo, 2015, Discovery of 2-[1-(4,4-difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): a potent, orally available, and highly selective PARP-1 inhibitor for cancer therapy, J Med Chem, 58, 6875, 10.1021/acs.jmedchem.5b00680 Johannes, 2021, Discovery of 5-{4-[(7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-N-methylpyridine-2-carboxamide (AZD5305): a PARP1-DNA trapper with high selectivity for PARP1 over PARP2 and other PARPs, J Med Chem, 64, 14498, 10.1021/acs.jmedchem.1c01012 Illuzzi, 2022, Preclinical characterization of AZD5305, A next-generation, highly selective PARP1 inhibitor and trapper, Clin Cancer Res, 28, 4724, 10.1158/1078-0432.CCR-22-0301 Yap, 2022, PETRA: First in class, first in human trial of the next generation PARP1-selective inhibitor AZD5305 in patients (pts) with BRCA1/2, PALB2 or RAD51C/D mutations Cruz, 2018, RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer, Ann Oncol, 29, 1203, 10.1093/annonc/mdy099 Rottenberg, 2008, High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs, Proc Natl Acad Sci U S A, 105, 17079, 10.1073/pnas.0806092105 Heeke, 2020, Actionable co-alterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathway, Breast Cancer Res Treat, 184, 265, 10.1007/s10549-020-05849-2 Konstantinopoulos, 2015, Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer, Cancer Discov, 5, 1137, 10.1158/2159-8290.CD-15-0714 Zong, 2022, Comprehensive analysis of somatic reversion mutations in homologous recombination repair (HRR) genes in A large cohort of Chinese pan-cancer patients, J Cancer, 13, 1119, 10.7150/jca.65650 Ang, 2013, Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study, Clin Cancer Res, 19, 5485, 10.1158/1078-0432.CCR-13-1262 Weigelt, 2017, Diverse BRCA1 and BRCA2 reversion mutations in circulating cell-free DNA of therapy-resistant breast or ovarian cancer, Clin Cancer Res, 23, 6708, 10.1158/1078-0432.CCR-17-0544 Waks, 2020, Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer, Ann Oncol, 31, 590, 10.1016/j.annonc.2020.02.008 Tobalina, 2021, A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance, Ann Oncol, 32, 103, 10.1016/j.annonc.2020.10.470 Quigley, 2017, Analysis of circulating cell-free DNA identifies multiclonal heterogeneity of BRCA2 reversion mutations associated with resistance to PARP inhibitors, Cancer Discov, 7, 999, 10.1158/2159-8290.CD-17-0146 Lin, 2019, BRCA reversion mutations in circulating tumor DNA predict primary and acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma, Cancer Discov, 9, 210, 10.1158/2159-8290.CD-18-0715 Mirman, 2020, 53BP1:a DSB escort, Genes Dev, 34, 7, 10.1101/gad.333237.119 Setiaputra, 2019, Shieldin - the protector of DNA ends, EMBO Rep, 20, 10.15252/embr.201847560 Panier, 2014, Double-strand break repair: 53BP1 comes into focus, Nat Rev Mol Cell Biol, 15, 7, 10.1038/nrm3719 Mirman, 2022, 53BP1-shieldin-dependent DSB processing in BRCA1-deficient cells requires CST-Polα-primase fill-in synthesis, Nat Cell Biol, 24, 51, 10.1038/s41556-021-00812-9 Noordermeer, 2018, The shieldin complex mediates 53BP1-dependent DNA repair, Nature, 560, 117, 10.1038/s41586-018-0340-7 Dev, 2018, Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells, Nat Cell Biol, 20, 954, 10.1038/s41556-018-0140-1 He, 2018, DYNLL1 binds to MRE11 to limit DNA end resection in BRCA1-deficient cells, Nature, 563, 522, 10.1038/s41586-018-0670-5 Tan, 2021, C/EBPβ promotes poly(ADP-ribose) polymerase inhibitor resistance by enhancing homologous recombination repair in high-grade serous ovarian cancer, Oncogene, 40, 3845, 10.1038/s41388-021-01788-4 Chaudhuri, 2016, Replication fork stability confers chemoresistance in BRCA-deficient cells, Nature, 535, 382, 10.1038/nature18325 Taglialatela, 2017, Restoration of replication fork stability in BRCA1- and BRCA2-deficient cells by inactivation of SNF2-family fork remodelers, Mol Cell, 68, 414, 10.1016/j.molcel.2017.09.036 Rondinelli, 2017, EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation, Nat Cell Biol, 19, 1371, 10.1038/ncb3626 Veeck, 2010, BRCA1 CpG island hypermethylation predicts sensitivity to poly(adenosine diphosphate)-ribose polymerase inhibitors, J Clin Oncol, 28, e563, 10.1200/JCO.2010.30.1010 Dobrovic, 1997, Methylation of the BRCA1 gene in sporadic breast cancer, Cancer Res, 57, 3347 Ashworth, 2008, A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair, J Clin Oncol, 26, 3785, 10.1200/JCO.2008.16.0812 Kondrashova, 2018, Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma, Nat Commun, 9, 3970, 10.1038/s41467-018-05564-z Nesic, 2021, Acquired RAD51C promoter methylation loss causes PARP inhibitor resistance in high-grade serous ovarian carcinoma, Cancer Res, 81, 4709, 10.1158/0008-5472.CAN-21-0774 Gao, 2013, Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal, Sci Signal, 6, pl1, 10.1126/scisignal.2004088 Wilke, 1997, Isolation of human and mouse HMG2a cDNAs: evidence for an HMG2a-specific 3' untranslated region, Gene, 198, 269, 10.1016/S0378-1119(97)00324-7 Li, 2020, Targeting HMGB3/hTERT axis for radioresistance in cervical cancer, J Exp Clin Cancer Res, 39, 243, 10.1186/s13046-020-01737-1 Li, 2016, miR-27b is epigenetically downregulated in tamoxifen resistant breast cancer cells due to promoter methylation and regulates tamoxifen sensitivity by targeting HMGB3, Biochem Biophys Res Commun, 477, 768, 10.1016/j.bbrc.2016.06.133 Mukherjee, 2019, Targeting the high-mobility group box 3 protein sensitizes chemoresistant ovarian cancer cells to cisplatin, Cancer Res, 79, 3185, 10.1158/0008-5472.CAN-19-0542 Ma, 2022, HMGB3 promotes PARP inhibitor resistance through interacting with PARP1 in ovarian cancer, Cell Death Dis, 13, 263, 10.1038/s41419-022-04670-7 Yu, 2007, Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment, Nat Rev Immunol, 7, 41, 10.1038/nri1995 Zou, 2020, Targeting STAT3 in cancer immunotherapy, Mol Cancer, 19, 145, 10.1186/s12943-020-01258-7 Ding, 2019, PARP1 suppresses the transcription of PD-L1 by poly(ADP-ribosyl)ating STAT3, Cancer Immunol Res, 7, 136, 10.1158/2326-6066.CIR-18-0071 Martincuks, 2021, PARP inhibition activates STAT3 in both tumor and immune cells underlying therapy resistance and immunosuppression in ovarian cancer, Front Oncol, 11, 10.3389/fonc.2021.724104 Färkkilä, 2021, Heterogeneity and clonal evolution of acquired PARP inhibitor resistance in TP53- and BRCA1-deficient cells, Cancer Res, 81, 2774, 10.1158/0008-5472.CAN-20-2912 Hammond, 2014, The meaning, measurement and modification of hypoxia in the laboratory and the clinic, Clin Oncol, 26, 277, 10.1016/j.clon.2014.02.002 Brown, 2000, Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies, Mol Med Today, 6, 157, 10.1016/S1357-4310(00)01677-4 Mehibel, 2021, Eliminating hypoxic tumor cells improves response to PARP inhibitors in homologous recombination-deficient cancer models, J Clin Invest, 131, 10.1172/JCI146256 Chan, 2010, Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment, Cancer Res, 70, 8045, 10.1158/0008-5472.CAN-10-2352 Gachechiladze, 2017, RAD51 as a potential surrogate marker for DNA repair capacity in solid malignancies, Int J Cancer, 141, 1286, 10.1002/ijc.30764 Castroviejo-Bermejo, 2018, A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation, EMBO Mol Med, 10, 10.15252/emmm.201809172 Pellegrino, 2022, Preclinical in vivo validation of the RAD51 test for identification of homologous recombination-deficient tumors and patient stratification, Cancer Res, 82, 1646, 10.1158/0008-5472.CAN-21-2409 Liu, 2017, RAD51 mediates resistance of cancer stem cells to PARP inhibition in triple-negative breast cancer, Clin Cancer Res, 23, 514, 10.1158/1078-0432.CCR-15-1348 Heeke, 2018, Prevalence of homologous recombination-related gene mutations across multiple cancer types, JCO Precis Oncol, 10.1200/PO.17.00286 Ipsen, 2022, A genome-wide CRISPR-Cas9 knockout screen identifies novel PARP inhibitor resistance genes in prostate cancer, Oncogene, 41, 4271, 10.1038/s41388-022-02427-2 Peng, 2019, The deubiquitylating enzyme USP15 regulates homologous recombination repair and cancer cell response to PARP inhibitors, Nat Commun, 10, 1224, 10.1038/s41467-019-09232-8 Sun, 2017, Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers, Sci Transl Med, 9, 10.1126/scitranslmed.aal5148 Yang, 2021, MEK inhibition remodels the immune landscape of mutant KRAS tumors to overcome resistance to PARP and immune checkpoint inhibitors, Cancer Res, 81, 2714, 10.1158/0008-5472.CAN-20-2370 Paes Dias, 2021, Loss of nuclear DNA ligase III reverts PARP inhibitor resistance in BRCA1/53BP1 double-deficient cells by exposing ssDNA gaps, Mol Cell, 81, 4692, 10.1016/j.molcel.2021.09.005 Taglialatela, 2021, REV1-Polζ maintains the viability of homologous recombination-deficient cancer cells through mutagenic repair of PRIMPOL-dependent ssDNA gaps, Mol Cell, 81, 4008, 10.1016/j.molcel.2021.08.016 Chen, 2019, Targeting dePARylation selectively suppresses DNA repair-defective and PARP inhibitor-resistant malignancies, Sci Adv, 5, 10.1126/sciadv.aav4340 Parmar, 2019, The CHK1 inhibitor prexasertib exhibits monotherapy activity in high-grade serous ovarian cancer models and sensitizes to PARP inhibition, Clin Cancer Res, 25, 6127, 10.1158/1078-0432.CCR-19-0448 Zhou, 2022, Inhibition of PKM2 enhances sensitivity of olaparib to ovarian cancer cells and induces DNA damage, Int J Biol Sci, 18, 1555, 10.7150/ijbs.62947 Kanakkanthara, 2022, Repurposing ceritinib induces DNA damage and enhances PARP inhibitor responses in high-grade serous ovarian carcinoma, Cancer Res, 82, 307, 10.1158/0008-5472.CAN-21-0732 Gabbasov, 2019, Targeted blockade of HSP90 impairs DNA-damage response proteins and increases the sensitivity of ovarian carcinoma cells to PARP inhibition, Cancer Biol Ther, 20, 1035, 10.1080/15384047.2019.1595279 Wang, 2022, STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer, Nat Commun, 13, 3022, 10.1038/s41467-022-30568-1 Li, 2017, Androgen receptor inhibitor-induced “BRCAness” and PARP inhibition are synthetically lethal for castration-resistant prostate cancer, Sci Signal, 10, 10.1126/scisignal.aam7479 Fugger, 2021, Targeting the nucleotide salvage factor DNPH1 sensitizes BRCA-deficient cells to PARP inhibitors, Science, 372, 156, 10.1126/science.abb4542 Li, 2022, The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatment, J Hematol Oncol, 15, 147, 10.1186/s13045-022-01360-x Gupta, 2022, Cell cycle checkpoints and beyond: exploiting the ATR/CHK1/WEE1 pathway for the treatment of PARP inhibitor–resistant cancer, Pharmacol Res, 178, 10.1016/j.phrs.2022.106162 Kim, 2020, Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models, Nat Commun, 11, 3726, 10.1038/s41467-020-17127-2 Sharma, 2016, Clinical development of new drug-radiotherapy combinations, Nat Rev Clin Oncol, 13, 627, 10.1038/nrclinonc.2016.79 Veuger, 2009, Ionizing radiation-induced NF-kappaB activation requires PARP-1 function to confer radioresistance, Oncogene, 28, 832, 10.1038/onc.2008.439 Boudra, 2015, PARP-2 depletion results in lower radiation cell survival but cell line-specific differences in poly(ADP-ribose) levels, Cell Mol Life Sci, 72, 1585, 10.1007/s00018-014-1765-2 Mao, 2018, PARP inhibitor olaparib sensitizes cholangiocarcinoma cells to radiation, Cancer Med, 7, 1285, 10.1002/cam4.1318 Bi, 2018, Radiosensitization by the PARP inhibitor olaparib in BRCA1-proficient and deficient high-grade serous ovarian carcinomas, Gynecol Oncol, 150, 534, 10.1016/j.ygyno.2018.07.002 Mangoni, 2018, Enhancement of soft tissue sarcoma cell radiosensitivity by poly(ADP-ribose) polymerase-1 inhibitors, Radiat Res, 190, 464, 10.1667/RR15035.1 Abbotts, 2019, DNA methyltransferase inhibitors induce a BRCAness phenotype that sensitizes NSCLC to PARP inhibitor and ionizing radiation, Proc Natl Acad Sci U S A, 116, 22609, 10.1073/pnas.1903765116 Wilson, 2019, Nitric oxide-donor/PARP-inhibitor combination: a new approach for sensitization to ionizing radiation, Redox Biol, 24, 10.1016/j.redox.2019.101169 Verhagen, 2015, Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells, Radiother Oncol, 116, 358, 10.1016/j.radonc.2015.03.028 Sizemore, 2018, Synthetic lethality of PARP inhibition and ionizing radiation is p53-dependent, Mol Cancer Res, 16, 1092, 10.1158/1541-7786.MCR-18-0106 Riley, 2019, Delivery technologies for cancer immunotherapy, Nat Rev Drug Discov, 18, 175, 10.1038/s41573-018-0006-z Wang, 2019, Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models, Sci Rep, 9, 1853, 10.1038/s41598-019-38534-6 Lassen, 2019, Combining PARP inhibition with PD-1 inhibitors, Lancet Oncol, 20, 1196, 10.1016/S1470-2045(19)30509-1 Vinayak, 2019, Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer, JAMA Oncol, 5, 1132, 10.1001/jamaoncol.2019.1029 Konstantinopoulos, 2019, Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma, JAMA Oncol, 5, 1141, 10.1001/jamaoncol.2019.1048 Sandhu, 2019, PROfound: phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations, Ann Oncol, 30, ix188, 10.1093/annonc/mdz446.007 Yap, 2022, IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin-paclitaxel, with or without bevacizumab in patients with advanced cancer, J Immunother Cancer, 10, 10.1136/jitc-2021-003924 Powles, 2021, An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer, Nat Med, 27, 793, 10.1038/s41591-021-01317-6 Färkkilä, 2020, Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer, Nat Commun, 11, 1459, 10.1038/s41467-020-15315-8